Share Price and Basic Stock Data
Last Updated: November 3, 2025, 10:08 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Sun Pharma Advanced Research Company Ltd operates in the miscellaneous sector, with its stock currently priced at ₹142 and a market capitalization of ₹4,616 Cr. The company has shown significant volatility in its revenue trends, recording sales of ₹28 Cr in June 2022 and peaking at ₹131 Cr in December 2022. However, subsequent quarters revealed a decline, with sales dropping to ₹21 Cr by September 2023 and further to ₹14 Cr in December 2023. The trailing twelve-month (TTM) sales stood at ₹65 Cr, indicating a challenging revenue environment. Historical performance shows a stark contrast, as annual sales reached ₹253 Cr in March 2021 but fell to ₹239 Cr in March 2023. This decline reflects potential operational inefficiencies and market challenges that the company must navigate to regain growth momentum.
Profitability and Efficiency Metrics
Sun Pharma Advanced Research Company Ltd’s profitability metrics reveal significant challenges. The operating profit margin (OPM) stood at a staggering -543% for the latest quarter, indicating severe losses relative to sales. The company has reported negative net profits consistently, with a net profit of -₹300 Cr and an EPS of -10.55 for March 2025. The interest coverage ratio (ICR) further complicates the outlook, recorded at -35.55x, highlighting difficulties in meeting interest obligations. Efficiency metrics are also concerning, with a cash conversion cycle of 82 days and a return on capital employed (ROCE) of 298%, which, while a positive figure, must be interpreted alongside high leverage and negative profitability. Such metrics indicate that the company is struggling to convert its investments into profitable returns.
Balance Sheet Strength and Financial Ratios
The balance sheet of Sun Pharma Advanced Research Company Ltd shows a precarious financial position. Reserves reported at -₹253 Cr and borrowings of ₹265 Cr indicate a negative net worth situation, which is concerning for potential investors. The company’s current ratio is alarmingly low at 0.07, suggesting liquidity issues, while the long-term debt to equity ratio stands at -0.46, reflecting high financial leverage. The price-to-book value ratio at -22.14x indicates that the market values the company significantly lower than its book value, which is a red flag for investor confidence. Furthermore, the enterprise value of ₹5,059.27 Cr against the net operating revenue highlights a high valuation relative to revenue, raising questions about sustainability given the ongoing losses.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Sun Pharma Advanced Research Company Ltd illustrates a strong promoter presence, holding 65.67% of the company as of June 2025. Foreign institutional investors (FIIs) have reduced their stake to 1.47%, while domestic institutional investors (DIIs) hold 0.97%. The public shareholding stands at 31.88%, with a total of 1,40,724 shareholders. The decline in FII interest can be interpreted as a lack of confidence in the company’s recovery potential. The stability of the promoter holding may provide some reassurance, but the overall decrease in institutional investment signals caution. This trend could affect the stock’s liquidity and market perception, impacting the company’s ability to attract further investment.
Outlook, Risks, and Final Insight
Sun Pharma Advanced Research Company Ltd faces a challenging outlook driven by significant operational losses and weak revenue generation. Key risks include ongoing negative profitability, high leverage, and a deteriorating liquidity position, which could hinder future growth prospects. The company must address its operational inefficiencies to stabilize revenue while managing its debt effectively. On the other hand, strengths such as a strong promoter backing and a high ROCE relative to its peers may offer some resilience. If the company can implement effective turnaround strategies, it may regain investor confidence and improve its market position. However, failure to do so may lead to continued financial distress and reduced shareholder value. A cautious approach is warranted for potential investors as the company navigates these turbulent waters.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Sun Pharma Advanced Research Company Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Mipco Seamless Rings (Gujarat) Ltd | 8.94 Cr. | 25.0 | 37.4/22.0 | 9.18 | 0.00 % | % | % | 10.0 | |
| MPIL Corporation Ltd | 31.4 Cr. | 550 | 787/447 | 238 | 0.08 % | 12.8 % | 15.5 % | 10.0 | |
| FGP Ltd | 11.9 Cr. | 10.0 | 13.7/7.32 | 3.09 | 0.00 % | 0.00 % | 0.89 % | 10.0 | |
| Logica Infoway Ltd | 362 Cr. | 203 | 272/173 | 34.4 | 49.4 | 0.00 % | 14.3 % | 14.1 % | 10.0 |
| CRP Risk Management Ltd | 10.8 Cr. | 6.18 | 11.1/5.61 | 34.6 | 0.00 % | 0.00 % | 0.00 % | 10.0 | |
| Industry Average | 8,475.75 Cr | 276.96 | 43.30 | 105.94 | 0.03% | 48.42% | 7.44% | 9.00 |
All Competitor Stocks of Sun Pharma Advanced Research Company Ltd
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 28 | 32 | 131 | 48 | 24 | 21 | 14 | 17 | 17 | 13 | 15 | 27 | 10 |
| Expenses | 107 | 94 | 115 | 137 | 126 | 113 | 116 | 124 | 112 | 117 | 89 | 81 | 62 |
| Operating Profit | -78 | -63 | 16 | -90 | -102 | -91 | -103 | -108 | -95 | -104 | -74 | -54 | -52 |
| OPM % | -275% | -198% | 12% | -188% | -427% | -432% | -740% | -649% | -566% | -808% | -499% | -198% | -543% |
| Other Income | 0 | 0 | 0 | 11 | 10 | 8 | 6 | 4 | 2 | 0 | 0 | 0 | 9 |
| Interest | 2 | 3 | 3 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 | 5 | 6 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Profit before tax | -82 | -68 | 10 | -82 | -95 | -86 | -100 | -107 | -97 | -108 | -80 | -61 | -52 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -82 | -68 | 10 | -82 | -95 | -86 | -100 | -107 | -97 | -108 | -80 | -61 | -52 |
| EPS in Rs | -3.03 | -2.52 | 0.37 | -2.53 | -2.94 | -2.66 | -3.07 | -3.29 | -2.98 | -3.32 | -2.46 | -1.88 | -1.60 |
Last Updated: August 20, 2025, 3:00 am
Below is a detailed analysis of the quarterly data for Sun Pharma Advanced Research Company Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 10.00 Cr.. The value appears to be declining and may need further review. It has decreased from 27.00 Cr. (Mar 2025) to 10.00 Cr., marking a decrease of 17.00 Cr..
- For Expenses, as of Jun 2025, the value is 62.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 81.00 Cr. (Mar 2025) to 62.00 Cr., marking a decrease of 19.00 Cr..
- For Operating Profit, as of Jun 2025, the value is -52.00 Cr.. The value appears strong and on an upward trend. It has increased from -54.00 Cr. (Mar 2025) to -52.00 Cr., marking an increase of 2.00 Cr..
- For OPM %, as of Jun 2025, the value is -543.00%. The value appears to be declining and may need further review. It has decreased from -198.00% (Mar 2025) to -543.00%, marking a decrease of 345.00%.
- For Other Income, as of Jun 2025, the value is 9.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 9.00 Cr., marking an increase of 9.00 Cr..
- For Interest, as of Jun 2025, the value is 6.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.00 Cr. (Mar 2025) to 6.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -52.00 Cr.. The value appears strong and on an upward trend. It has increased from -61.00 Cr. (Mar 2025) to -52.00 Cr., marking an increase of 9.00 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is -52.00 Cr.. The value appears strong and on an upward trend. It has increased from -61.00 Cr. (Mar 2025) to -52.00 Cr., marking an increase of 9.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -1.60. The value appears strong and on an upward trend. It has increased from -1.88 (Mar 2025) to -1.60, marking an increase of 0.28.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 22, 2025, 7:02 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 167 | 156 | 161 | 181 | 78 | 183 | 77 | 253 | 137 | 239 | 76 | 72 | 65 |
| Expenses | 134 | 191 | 224 | 304 | 321 | 334 | 387 | 388 | 324 | 453 | 479 | 399 | 349 |
| Operating Profit | 34 | -35 | -63 | -123 | -243 | -151 | -310 | -135 | -187 | -214 | -404 | -327 | -284 |
| OPM % | 20% | -23% | -39% | -68% | -310% | -83% | -404% | -53% | -136% | -90% | -534% | -456% | -440% |
| Other Income | 10 | 3 | 3 | 14 | 54 | 14 | 10 | 5 | 7 | 11 | 29 | 2 | 9 |
| Interest | 6 | 0 | 2 | 2 | 0 | 0 | 3 | 11 | 13 | 8 | 2 | 9 | 15 |
| Depreciation | 4 | 7 | 8 | 8 | 8 | 8 | 9 | 11 | 10 | 12 | 12 | 11 | 11 |
| Profit before tax | 34 | -40 | -70 | -119 | -197 | -145 | -312 | -151 | -203 | -223 | -388 | -345 | -300 |
| Tax % | 12% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |
| Net Profit | 30 | -40 | -70 | -119 | -197 | -145 | -312 | -151 | -203 | -223 | -388 | -345 | -300 |
| EPS in Rs | 1.23 | -1.60 | -2.83 | -4.82 | -7.85 | -5.55 | -11.92 | -5.77 | -7.48 | -6.86 | -11.96 | -10.64 | -9.26 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -233.33% | -75.00% | -70.00% | -65.55% | 26.40% | -115.17% | 51.60% | -34.44% | -9.85% | -73.99% | 11.08% |
| Change in YoY Net Profit Growth (%) | 0.00% | 158.33% | 5.00% | 4.45% | 91.94% | -141.57% | 166.77% | -86.04% | 24.58% | -64.14% | 85.07% |
Sun Pharma Advanced Research Company Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -7% |
| 5 Years: | -1% |
| 3 Years: | -19% |
| TTM: | -6% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -2% |
| 3 Years: | -30% |
| TTM: | 23% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -9% |
| 5 Years: | -4% |
| 3 Years: | -14% |
| 1 Year: | -36% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Last Updated: September 5, 2025, 1:36 pm
Balance Sheet
Last Updated: July 25, 2025, 2:16 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 24 | 24 | 24 | 25 | 25 | 26 | 26 | 26 | 27 | 32 | 32 | 32 |
| Reserves | 116 | 76 | 8 | 133 | 160 | 270 | -45 | -194 | 4 | 480 | 92 | -253 |
| Borrowings | 5 | 4 | 56 | 3 | 2 | 2 | 67 | 236 | 79 | 16 | 56 | 265 |
| Other Liabilities | 39 | 39 | 75 | 111 | 122 | 101 | 224 | 162 | 170 | 302 | 305 | 284 |
| Total Liabilities | 184 | 143 | 163 | 273 | 309 | 398 | 273 | 230 | 280 | 830 | 486 | 329 |
| Fixed Assets | 64 | 67 | 70 | 69 | 52 | 58 | 104 | 91 | 92 | 106 | 103 | 95 |
| CWIP | 1 | 0 | 1 | 1 | 3 | 24 | 32 | 5 | 26 | 27 | 44 | 54 |
| Investments | 6 | 0 | 0 | 10 | 108 | 211 | 8 | 6 | 12 | 291 | 2 | 0 |
| Other Assets | 112 | 76 | 92 | 192 | 146 | 106 | 128 | 127 | 150 | 406 | 338 | 179 |
| Total Assets | 184 | 143 | 163 | 273 | 309 | 398 | 273 | 230 | 280 | 830 | 486 | 329 |
Below is a detailed analysis of the balance sheet data for Sun Pharma Advanced Research Company Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 32.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 32.00 Cr..
- For Reserves, as of Mar 2025, the value is -253.00 Cr.. The value appears to be declining and may need further review. It has decreased from 92.00 Cr. (Mar 2024) to -253.00 Cr., marking a decrease of 345.00 Cr..
- For Borrowings, as of Mar 2025, the value is 265.00 Cr.. The value appears to be increasing, which may not be favorable. However, Reserves are negative, which is a major warning sign. It has increased from 56.00 Cr. (Mar 2024) to 265.00 Cr., marking an increase of 209.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 284.00 Cr.. The value appears to be improving (decreasing). It has decreased from 305.00 Cr. (Mar 2024) to 284.00 Cr., marking a decrease of 21.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 329.00 Cr.. The value appears to be improving (decreasing). It has decreased from 486.00 Cr. (Mar 2024) to 329.00 Cr., marking a decrease of 157.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 95.00 Cr.. The value appears to be declining and may need further review. It has decreased from 103.00 Cr. (Mar 2024) to 95.00 Cr., marking a decrease of 8.00 Cr..
- For CWIP, as of Mar 2025, the value is 54.00 Cr.. The value appears strong and on an upward trend. It has increased from 44.00 Cr. (Mar 2024) to 54.00 Cr., marking an increase of 10.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 2.00 Cr..
- For Other Assets, as of Mar 2025, the value is 179.00 Cr.. The value appears to be declining and may need further review. It has decreased from 338.00 Cr. (Mar 2024) to 179.00 Cr., marking a decrease of 159.00 Cr..
- For Total Assets, as of Mar 2025, the value is 329.00 Cr.. The value appears to be declining and may need further review. It has decreased from 486.00 Cr. (Mar 2024) to 329.00 Cr., marking a decrease of 157.00 Cr..
However, the Borrowings (265.00 Cr.) are higher than the Reserves (-253.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 29.00 | -39.00 | -119.00 | -126.00 | -245.00 | -153.00 | -377.00 | -371.00 | -266.00 | -230.00 | -460.00 | -592.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 47 | 21 | 78 | 82 | 20 | 76 | 25 | 74 | 50 | 75 | 82 |
| Inventory Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 61 | 47 | 21 | 78 | 82 | 20 | 76 | 25 | 74 | 50 | 75 | 82 |
| Working Capital Days | 127 | 20 | -161 | -60 | -232 | -98 | -842 | -268 | -301 | -193 | -746 | -1,778 |
| ROCE % | 21% | -32% | -71% | -94% | -143% | -62% | -183% | -242% | -218% | -67% | -109% | -298% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Small Cap Fund | 595,869 | 0.13 | 17.09 | 595,869 | 2025-04-22 17:25:19 | 0% |
| ITI Pharma and Healthcare Fund | 58,628 | 1.17 | 1.68 | 58,628 | 2025-04-22 17:25:19 | 0% |
| Nippon India Nifty Smallcap 250 Index Fund | 48,528 | 0.14 | 1.39 | 48,528 | 2025-04-22 17:25:19 | 0% |
| Motilal Oswal Nifty Smallcap 250 Index Fund | 30,326 | 0.14 | 0.87 | 30,326 | 2025-04-22 17:25:19 | 0% |
| SBI Nifty Smallcap 250 Index Fund | 23,805 | 0.14 | 0.68 | 23,805 | 2025-04-22 17:25:19 | 0% |
| ICICI Prudential Nifty Smallcap 250 Index Fund | 11,330 | 0.14 | 0.32 | 11,330 | 2025-04-22 17:25:20 | 0% |
| HDFC NIFTY Smallcap 250 ETF | 6,573 | 0.14 | 0.19 | 6,573 | 2025-04-22 17:25:20 | 0% |
| HDFC Nifty Smallcap 250 Index Fund | 5,301 | 0.14 | 0.15 | 5,301 | 2025-04-22 17:25:20 | 0% |
| Motilal Oswal Nifty 500 Index Fund | 3,060 | 0.01 | 0.09 | 3,060 | 2025-04-22 17:25:20 | 0% |
| Edelweiss Nifty Smallcap 250 Index Fund | 1,234 | 0.14 | 0.04 | 1,234 | 2025-04-22 17:25:20 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | -10.55 | -11.93 | -7.82 |
| Diluted EPS (Rs.) | -10.55 | -11.93 | -7.82 |
| Cash EPS (Rs.) | -10.17 | -11.55 | -6.50 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | -6.68 | 3.88 | 15.80 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | -6.68 | 3.88 | 15.80 |
| Revenue From Operations / Share (Rs.) | 2.21 | 2.33 | 7.36 |
| PBDIT / Share (Rs.) | -9.90 | -11.48 | -6.26 |
| PBIT / Share (Rs.) | -10.28 | -11.87 | -6.62 |
| PBT / Share (Rs.) | -10.56 | -11.92 | -6.86 |
| Net Profit / Share (Rs.) | -10.55 | -11.93 | -6.86 |
| NP After MI And SOA / Share (Rs.) | -10.55 | -11.93 | -6.86 |
| PBDIT Margin (%) | -447.77 | -493.24 | -85.09 |
| PBIT Margin (%) | -465.04 | -509.80 | -90.01 |
| PBT Margin (%) | -477.63 | -512.05 | -93.21 |
| Net Profit Margin (%) | -477.25 | -512.55 | -93.21 |
| NP After MI And SOA Margin (%) | -477.25 | -512.55 | -93.21 |
| Return on Networth / Equity (%) | 0.00 | -307.91 | -43.40 |
| Return on Capital Employeed (%) | 862.23 | -154.06 | -33.00 |
| Return On Assets (%) | -102.07 | -75.18 | -26.81 |
| Long Term Debt / Equity (X) | -0.46 | 0.00 | 0.00 |
| Total Debt / Equity (X) | -1.19 | 0.37 | 0.00 |
| Asset Turnover Ratio (%) | 0.16 | 0.11 | 0.00 |
| Current Ratio (X) | 0.07 | 1.02 | 2.54 |
| Quick Ratio (X) | 0.07 | 1.02 | 2.54 |
| Interest Coverage Ratio (X) | -35.55 | -219.89 | -26.61 |
| Interest Coverage Ratio (Post Tax) (X) | -36.89 | -227.50 | -28.15 |
| Enterprise Value (Cr.) | 5059.27 | 11897.66 | 5712.17 |
| EV / Net Operating Revenue (X) | 70.50 | 157.49 | 23.92 |
| EV / EBITDA (X) | -15.74 | -31.93 | -28.11 |
| MarketCap / Net Operating Revenue (X) | 66.93 | 158.92 | 24.39 |
| Price / BV (X) | -22.14 | 95.47 | 11.36 |
| Price / Net Operating Revenue (X) | 66.93 | 158.93 | 24.39 |
| EarningsYield | -0.07 | -0.03 | -0.03 |
After reviewing the key financial ratios for Sun Pharma Advanced Research Company Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -10.55. This value is below the healthy minimum of 5. It has increased from -11.93 (Mar 24) to -10.55, marking an increase of 1.38.
- For Diluted EPS (Rs.), as of Mar 25, the value is -10.55. This value is below the healthy minimum of 5. It has increased from -11.93 (Mar 24) to -10.55, marking an increase of 1.38.
- For Cash EPS (Rs.), as of Mar 25, the value is -10.17. This value is below the healthy minimum of 3. It has increased from -11.55 (Mar 24) to -10.17, marking an increase of 1.38.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -6.68. It has decreased from 3.88 (Mar 24) to -6.68, marking a decrease of 10.56.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -6.68. It has decreased from 3.88 (Mar 24) to -6.68, marking a decrease of 10.56.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 2.21. It has decreased from 2.33 (Mar 24) to 2.21, marking a decrease of 0.12.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -9.90. This value is below the healthy minimum of 2. It has increased from -11.48 (Mar 24) to -9.90, marking an increase of 1.58.
- For PBIT / Share (Rs.), as of Mar 25, the value is -10.28. This value is below the healthy minimum of 0. It has increased from -11.87 (Mar 24) to -10.28, marking an increase of 1.59.
- For PBT / Share (Rs.), as of Mar 25, the value is -10.56. This value is below the healthy minimum of 0. It has increased from -11.92 (Mar 24) to -10.56, marking an increase of 1.36.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -10.55. This value is below the healthy minimum of 2. It has increased from -11.93 (Mar 24) to -10.55, marking an increase of 1.38.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -10.55. This value is below the healthy minimum of 2. It has increased from -11.93 (Mar 24) to -10.55, marking an increase of 1.38.
- For PBDIT Margin (%), as of Mar 25, the value is -447.77. This value is below the healthy minimum of 10. It has increased from -493.24 (Mar 24) to -447.77, marking an increase of 45.47.
- For PBIT Margin (%), as of Mar 25, the value is -465.04. This value is below the healthy minimum of 10. It has increased from -509.80 (Mar 24) to -465.04, marking an increase of 44.76.
- For PBT Margin (%), as of Mar 25, the value is -477.63. This value is below the healthy minimum of 10. It has increased from -512.05 (Mar 24) to -477.63, marking an increase of 34.42.
- For Net Profit Margin (%), as of Mar 25, the value is -477.25. This value is below the healthy minimum of 5. It has increased from -512.55 (Mar 24) to -477.25, marking an increase of 35.30.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -477.25. This value is below the healthy minimum of 8. It has increased from -512.55 (Mar 24) to -477.25, marking an increase of 35.30.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 15. It has increased from -307.91 (Mar 24) to 0.00, marking an increase of 307.91.
- For Return on Capital Employeed (%), as of Mar 25, the value is 862.23. This value is within the healthy range. It has increased from -154.06 (Mar 24) to 862.23, marking an increase of 1,016.29.
- For Return On Assets (%), as of Mar 25, the value is -102.07. This value is below the healthy minimum of 5. It has decreased from -75.18 (Mar 24) to -102.07, marking a decrease of 26.89.
- For Long Term Debt / Equity (X), as of Mar 25, the value is -0.46. This value is below the healthy minimum of 0.2. It has decreased from 0.00 (Mar 24) to -0.46, marking a decrease of 0.46.
- For Total Debt / Equity (X), as of Mar 25, the value is -1.19. This value is within the healthy range. It has decreased from 0.37 (Mar 24) to -1.19, marking a decrease of 1.56.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.16. It has increased from 0.11 (Mar 24) to 0.16, marking an increase of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 0.07. This value is below the healthy minimum of 1.5. It has decreased from 1.02 (Mar 24) to 0.07, marking a decrease of 0.95.
- For Quick Ratio (X), as of Mar 25, the value is 0.07. This value is below the healthy minimum of 1. It has decreased from 1.02 (Mar 24) to 0.07, marking a decrease of 0.95.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -35.55. This value is below the healthy minimum of 3. It has increased from -219.89 (Mar 24) to -35.55, marking an increase of 184.34.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -36.89. This value is below the healthy minimum of 3. It has increased from -227.50 (Mar 24) to -36.89, marking an increase of 190.61.
- For Enterprise Value (Cr.), as of Mar 25, the value is 5,059.27. It has decreased from 11,897.66 (Mar 24) to 5,059.27, marking a decrease of 6,838.39.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 70.50. This value exceeds the healthy maximum of 3. It has decreased from 157.49 (Mar 24) to 70.50, marking a decrease of 86.99.
- For EV / EBITDA (X), as of Mar 25, the value is -15.74. This value is below the healthy minimum of 5. It has increased from -31.93 (Mar 24) to -15.74, marking an increase of 16.19.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 66.93. This value exceeds the healthy maximum of 3. It has decreased from 158.92 (Mar 24) to 66.93, marking a decrease of 91.99.
- For Price / BV (X), as of Mar 25, the value is -22.14. This value is below the healthy minimum of 1. It has decreased from 95.47 (Mar 24) to -22.14, marking a decrease of 117.61.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 66.93. This value exceeds the healthy maximum of 3. It has decreased from 158.93 (Mar 24) to 66.93, marking a decrease of 92.00.
- For EarningsYield, as of Mar 25, the value is -0.07. This value is below the healthy minimum of 5. It has decreased from -0.03 (Mar 24) to -0.07, marking a decrease of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sun Pharma Advanced Research Company Ltd:
- Net Profit Margin: -477.25%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 862.23% (Industry Average ROCE: 48.42%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0% (Industry Average ROE: 7.44%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -36.89
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.07
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 43.3)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: -1.19
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -477.25%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Research Services | Plot No. 5 & 6/1, Savli G.I.D.C. Estate, Savli - Vadodara Highway, Vadodra District Gujarat 391775 | secretarial@sparcmail.com http://www.sparc.life |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Dilip S Shanghvi | Chairman & Non-Exe.Director |
| Dr. T Rajamannar | Non Executive Director |
| Ms. Vidhi Shanghvi | Non Executive Director |
| Mr. Venkateswarlu Jasti | Independent Director |
| Ms. Bhavna Doshi | Independent Director |
| Dr. Ferzaan Engineer | Independent Director |
| Dr. Robert J Spiegel | Independent Director |
| Mrs. Rekha Warriar | Independent Director |
FAQ
What is the intrinsic value of Sun Pharma Advanced Research Company Ltd?
Sun Pharma Advanced Research Company Ltd's intrinsic value (as of 03 November 2025) is 12.48 which is 91.09% lower the current market price of 140.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 4,553 Cr. market cap, FY2025-2026 high/low of 241/109, reserves of ₹-253 Cr, and liabilities of 329 Cr.
What is the Market Cap of Sun Pharma Advanced Research Company Ltd?
The Market Cap of Sun Pharma Advanced Research Company Ltd is 4,553 Cr..
What is the current Stock Price of Sun Pharma Advanced Research Company Ltd as on 03 November 2025?
The current stock price of Sun Pharma Advanced Research Company Ltd as on 03 November 2025 is 140.
What is the High / Low of Sun Pharma Advanced Research Company Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Sun Pharma Advanced Research Company Ltd stocks is 241/109.
What is the Stock P/E of Sun Pharma Advanced Research Company Ltd?
The Stock P/E of Sun Pharma Advanced Research Company Ltd is .
What is the Book Value of Sun Pharma Advanced Research Company Ltd?
The Book Value of Sun Pharma Advanced Research Company Ltd is 6.80.
What is the Dividend Yield of Sun Pharma Advanced Research Company Ltd?
The Dividend Yield of Sun Pharma Advanced Research Company Ltd is 0.00 %.
What is the ROCE of Sun Pharma Advanced Research Company Ltd?
The ROCE of Sun Pharma Advanced Research Company Ltd is 298 %.
What is the ROE of Sun Pharma Advanced Research Company Ltd?
The ROE of Sun Pharma Advanced Research Company Ltd is %.
What is the Face Value of Sun Pharma Advanced Research Company Ltd?
The Face Value of Sun Pharma Advanced Research Company Ltd is 1.00.